Investors / Portugal / Biovance Capital
Biovance Capital
Venture capital · Lisbon, Portugal · Europe
Biovance Capital is a biotech-focused venture fund backed by the European Investment Fund and other public and private investors. It invests in early-stage biopharma companies and works with entrepreneurs to build companies developing transformative treatments.
Invests inHealthcare & BiotechAI & Machine LearningEnterprise Software
In its own wordsbiotechbiopharmatherapeuticslife scienceshealthcare
Your fit with Biovance Capital
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsBiovance Capital lists 4 checked portfolio companies on its own site and is named in 3 funding rounds, 3 of them as lead. Its most frequent entry is Series A, 67% of the companies with a known first round. Its largest themes are Healthcare & Biotech (60%), AI & Machine Learning (20%) and Enterprise Software (20%). It invests most often alongside Angelini Ventures, Bionova Capital and Curie Capital.
Counts come from funding rounds that name Biovance Capital, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 33% |
| Series A | 67% |
| Series B | 0% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 1 | 1 |
| '26 | 2 | 2 |
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 60% | 15% |
| AI & Machine Learning | 20% | 18% |
| Enterprise Software | 20% | 8% |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Angelini Ventures | 1 |
| Bionova Capital | 1 |
| Curie Capital | 1 |
| Kurma Partners | 1 |
| Torrey Pines Investment | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers4100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with Angelini Ventures
Compare Biovance Capital head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Funds
as stated on its siteRecent portfolio activity
when companies last raised with Biovance Capital| Date | Company | Stage |
|---|---|---|
| 7 Sept 2026 | Series A Led | |
| 23 Mar 2026 | Seed Led | |
| 18 Sept 2025 | Series A Led |
Round details for Biovance Capital
Amounts, full round histories and every co-investor in Biovance Capital's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
4 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Biovance Capital invests in early-stage biopharma companies across Europe. | Healthcare & Biotech | Sept 2025Series A | Funding round | |
| Laigo provides a local enterprise AI solution for document-intensive industries to process documents and workflows without transferring company data outside the company | AI & Machine LearningEnterprise Software | Portfolio page | ||
| Laigo Bio develops targeted therapies using protein degradation technology | Healthcare & Biotech | Mar 2026Seed | Funding round | |
| Vaxdyn develops safe and effective vaccines against the most worrisome bacterial pathogens | Healthcare & Biotech | Sept 2026Series A | Page + round |
About this data
site last read 5 Nov 2026- Site
- biovancecapital.com
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 18 Sept 2025
- Companies checked
- 4
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Biovance Capital's profile as data
Pull Biovance Capital's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/biovancecapital.com
# also
GET /v1/firms/biovancecapital.com/portfolio
GET /v1/firms/biovancecapital.com/coinvestors
GET /v1/firms/biovancecapital.com/news